阿杜那单抗3期ENGAGE和EMERGE研究中淀粉样蛋白相关影像学异常的全基因组关联研究
本研究对接受阿杜那单抗治疗的ENGAGE和EMERGE试验中1691例欧洲裔参与者进行淀粉样蛋白相关影像学异常(ARIA)的全基因组关联研究,发现染色体19上APOE区域存在全基因组显著关联,ε4/ε4纯合子ARIA风险高于ε3/ε4杂合子,未发现APOE以外的全基因组显著关联。
要点
- 在阿杜那单抗治疗的ENGAGE和EMERGE试验参与者中,ARIA的全基因组关联研究仅发现APOE区域达到全基因组显著。
- APOE ε4/ε4纯合子发生ARIA-E、ARIA-H微出血和ARIA-H superficial siderosis的比值比分别为4.28、4.58、7.84。
- APOE ε4/ε4纯合子影像学严重ARIA的比值比(7.04-24.64)高于影像学轻度ARIA(3.19-5.00)。
核心结论
- APOE与ARIA风险存在强且全基因组显著的关联,APOE是ARIA发生率最强的遗传风险因素。
- 未来更大规模的研究可能更有把握检测APOE以外的关联。
研究设计与样本
- 对ENGAGE和EMERGE试验中接受阿杜那单抗治疗且至少有一次基线后MRI的1691例参与者进行ARIA的全基因组关联研究。
- 参与者为因阿尔茨海默病导致的轻度认知障碍或轻度阿尔茨海默病痴呆,且PET扫描淀粉样蛋白阳性。
- 所有参与者均接受定期MRI监测以检测和诊断ARIA。
- 分析人群来自意向治疗人群3285例,均有基因分型阵列数据;全部为欧洲裔,51%为女性,平均年龄70.3岁。
主要发现
- 31%的参与者发生ARIA-E,19%发生ARIA-H微出血,14%发生ARIA-H superficial siderosis。
- 在染色体19包含APOE的位点发现一个全基因组显著关联(p < 5.0 × 10-8)。
- APOE ε4/ε4纯合子与ARIA-E、ARIA-H微出血、ARIA-H superficial siderosis的关联(OR分别为4.28、4.58、7.84;p < 2.9 × 10-14)强于ε3/ε4杂合子(OR分别为1.74、1.46、3.14;p ≤ 0.03)。
- ε4/ε4纯合子中影像学严重ARIA的比值比(OR = 7.04-24.64,p ≤ 2.72 × 10-5)高于影像学轻度ARIA(OR = 3.19-5.00,p ≤ 1.37 × 10-5)。
- APOE ε4与症状性ARIA(ε4/ε4 OR = 3.64-9.52;p < 0.004)和无症状性ARIA(ε4/ε4 OR = 4.20-7.94,p < 1.7 × 10-11)均显著相关,但在ARIA病例中APOE似乎不调节症状状态。
局限性
- 未来更大规模的研究可能更有把握检测APOE以外的关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Amyloid-related imaging abnormalities (ARIA) were the most common adverse events reported in the phase 3 ENGAGE and EMERGE trials of aducanumab, an anti-amyloid monoclonal antibody. APOE ε4 carrier status has been shown to increase risk of ARIA in prior trials of aducanumab and other anti-amyloid therapies; however, the remainder of the human genome has not been evaluated for ARIA risk factors. Therefore, we sought to determine in a hypothesis-free manner whether genetic variants beyond APOE influence risk of ARIA in aducanumab-treated patients. METHODS: We performed genome-wide association studies (GWAS) of ARIA in participants in the ENGAGE and EMERGE trials. Participants had mild cognitive impairment due to Alzheimer disease or mild Alzheimer disease dementia and were amyloid-positive on PET scans. All participants underwent regular MRI monitoring to detect and diagnose ARIA. RESULTS: Of the 3,285 participants in the intent-to-treat population, this analysis included 1,691 with genotyping array data who received at least one dose of aducanumab with at least one post-baseline MRI. All participants in the study cohort were of European ancestry; 51% were female. The mean age was 70.3 years. 31% had ARIA-E, 19% had ARIA-H microhemorrhage, and 14% had ARIA-H superficial siderosis. We identified one genome-wide significant (p < 5.0 × 10-8) association at the chromosome 19 locus encompassing APOE. The APOE association with ARIA was stronger in ε4/ε4 homozygotes (OR = 4.28, 4.58, 7.84; p < 2.9 × 10-14 for ARIA-E, ARIA-H microhemorrhage, and ARIA-H superficial siderosis, respectively) than in ε3/ε4 heterozygotes (OR = 1.74, 1.46, 3.14; p ≤ 0.03). We found greater odds of radiographically severe ARIA (OR = 7.04-24.64, p ≤ 2.72 × 10-5) than radiographically mild ARIA (OR = 3.19-5.00, p ≤ 1.37 × 10-5) among ε4/ε4 homozygotes. APOE ε4 was also significantly associated with both symptomatic (ε4/ε4 OR = 3.64-9.52; p < 0.004) and asymptomatic (ε4/ε4 OR = 4.20-7.94, p < 1.7 × 10-11) cases, although among ARIA cases, APOE did not appear to modulate symptomatic status. No other genome-wide significant associations were found. DISCUSSION: We identified a strong, genome-wide significant association between APOE and risk of ARIA. Future, larger studies may be better powered to detect associations beyond APOE. These findings indicate that APOE is the strongest genetic risk factor of ARIA incidence, with implications for patient management and risk-benefit treatment decisions. TRIAL REGISTRATION INFORMATION: Both trials (ENGAGE [221AD301]: NCT02477800 and EMERGE [221AD302]: NCT02484547) were registered in June 2015 at clinicaltrials.gov and enrolled patients from August 2015 to July 2018.
引用
- Loomis SJ, Miller R, Castrillo-Viguera C, et al. Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies. Neurology. 2023. PMID: 38165296. doi:10.1212/WNL.0000000000207919
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。